Coya Therapeutics, Inc. Income Statement
COYA|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Coya Therapeutics, Inc. reported $8M in revenue and $21M in net loss for FY2025. Revenue increased 32.4% from FY2024 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $7.9M | $6.0M | $0 |
| SG&A Expense | $11.4M | $7.8M | $4.8M |
| R&D Expense | $16.7M | $5.5M | $4.4M |
| Operating Income | -$22.6M | -$7.9M | -$9.8M |
| Income Tax | $3.1K | $723.9K | $0 |
| Net Income | -$21.2M | -$8.0M | -$12.2M |
| EPS (Basic) | -$0.98 | -$0.79 | -$4.73 |
| EPS (Diluted) | -$0.98 | -$0.79 | -$4.73 |
| Shares Outstanding | 16.7M | 14.4M | 2.6M |
| Operating Margin | -283.9% | -131.7% | - |
| Profit Margin | -267.1% | -133.1% | - |